You are here

Controlled-Release Oxycodone/Acetaminophen Combo Gets Priority Review Status

Indication sought for treatment of acute pain (July 29)

The FDA has accepted a new drug application (NDA) for MNK-795 (Depomed/Mallinckrodt), a controlled-release oral formulation of oxycodone and acetaminophen that has been studied for the management of moderate-to-severe acute pain where the use of an opioid analgesic is appropriate.

The FDA granted the NDA a priority review, a designation given to drugs that, if approved, offer significant improvements in the safety or effectiveness of the treatment when compared with standard applications.

MNK-795 is a reformulation of existing controlled-substance analgesic combination products (oxycodone and acetaminophen) that may be indicated for moderate-to-severe acute pain. According to the compound’s developer (Mallinckrodt), MNK-795 was formulated as a low-dose product to meet an unmet clinical need in the market and also has certain abuse-deterrent characteristics.

Source: Depomed, Inc.; July 29, 2013.

Recent Headlines

Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring
Finding Could Spur New Targeted Treatments
But a ‘Serendipitous’ Finding Could Provide a Solution
New Drug Could Make Ears “Young” Again
DNA Changes May Help Predict Women at Risk